← Back to Search

Anti-metabolites

Continuous Infusion Gemcitabine for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by Advocate Lutheran General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 and over

Diagnosis of an advanced metastatic malignancy for which no curative therapy exists

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test the effectiveness of gemcitabine given as a continuous infusion to treat patients with advanced metastatic cancer.

Who is the study for?

This trial is for adults over 18 with advanced metastatic cancer where no curative treatment exists. They must have a certain level of neutrophils, platelets, and normal liver/kidney function. Pregnant or nursing women can't participate, and those who can have children must use contraception.Check my eligibility

What is being tested?

The study is testing the effectiveness of gemcitabine, a chemotherapy drug, when given as a continuous infusion to patients with advanced cancers that have spread to other parts of the body.See study design

What are the potential side effects?

Gemcitabine may cause side effects like flu-like symptoms, fatigue, nausea, low blood cell counts leading to increased infection risk or bleeding problems, and potential damage to the liver or kidneys.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My cancer is advanced and cannot be cured with existing treatments.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Advocate Lutheran General HospitalLead Sponsor

5 Previous Clinical Trials

3,154 Total Patients Enrolled

Brian L. Samuels, MDStudy ChairAdvocate Lutheran General Hospital

1 Previous Clinical Trials

72 Total Patients Enrolled

Media Library

Gemcitabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00020644 — Phase 1

Solid Tumors Clinical Trial 2023: Gemcitabine Highlights & Side Effects. Trial Name: NCT00020644 — Phase 1

Gemcitabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00020644 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this remedy been accepted by the Federal Drug Administration?

"Relative to the other two phases of clinical trials, Phase 1 studies provide limited evidence for safety and efficacy. As a result, our team at Power deems this treatment's risk profile to be rated as a one on their scale."

Answered by AI

Is this investigation actively seeking participants?

"The clinical trial records hosted on clinicaltrials.gov suggests that the study is not currently searching for participants, having been last updated in August 2013. Though this particular research programme may be inactive, 41 alternative trials are actively enrolling right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer

2000. "Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00020644.

All > Mci > Ic